Skip to main content
CBIO
NASDAQ Life Sciences

Crescent Biopharma Posts $289.4M Cash, Runway Into H2 2028 as Q3 Loss Widens

Tom Rudovsky · Reported by Wiseek News
More coverage: Biotech Stocks · Healthcare
Sentiment info
Neutral
Importance info
7
Price
$14.37
Mkt Cap
$533.758M
52W Low
$8.72
52W High
$27.41
52W Position info
65% above low
Off High info
48% below high
Rel. Volume info
0.6× avg
Market data snapshot near publication time

CBIO sits 65% above its 52-week low of $8.72.

Summary

Crescent ended September with $289.4M in cash and equivalents, including $133.4M in net proceeds from its July offering, and says that funds operations into H2 2028. The Q3 net loss widened to $37.7M from $24.6M a year earlier, with R&D up to $34.3M from $20.3M as clinical development expanded. That burn rate is the number that matters: the runway claim rests on spending not accelerating much beyond current levels. Operationally, ASCEND has dosed over 125 patients with monotherapy data, including first-line NSCLC, still guided to Q1 2027, and the first patient has been dosed in the global Phase 1/2 APOLLO trial. This follows the October 15 8-K laying out the clinical timeline and the October 5 FDA clearance for CR-002. The Q1 2027 ASCEND readout is the next binary event for the stock.

At the time of this announcement, CBIO was trading at $14.37 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $533.8M. The 52-week trading range was $8.72 to $27.41. This news item was assessed with neutral market sentiment and an importance score of 7 out of 10. Source: Wiseek News.


Price Chart

Share this article

Copied!

CBIO - Latest Insights

CBIO
Nov 12, 2026, 4:11 PM EST
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $14.37
Real-time Price: $15.42 info
Change: +$1.05 (+7%) info
Market Cap: $533.758M info
CBIO
Oct 15, 2026, 4:26 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $12.47
Real-time Price: $15.42 info
Change: +$2.95 (+24%) info
Market Cap: $533.758M info
CBIO
Oct 05, 2026, 7:30 AM EDT
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $14.91
Real-time Price: $15.42 info
Change: +$0.5107 (+3%) info
Market Cap: $533.758M info
CBIO
Jul 30, 2026, 9:25 AM EDT
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $14.77
Real-time Price: $15.42 info
Change: +$0.6507 (+4%) info
Market Cap: $533.758M info
CBIO
Jul 30, 2026, 7:36 AM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $14.77
Real-time Price: $15.42 info
Change: +$0.6507 (+4%) info
Market Cap: $533.758M info